Combatting future variants of SARS-CoV-2 using an in-silico peptide vaccine approach by targeting the spike protein. (April 2022)

• Record Type: Journal Article
• Authors: Biswas, Subhamoy; Dey, Sumanta; Chatterjee, Shreyans; Nandy, Ashesh
• Is Part Of: Medical hypotheses. Volume 161(2022)
• Publication Date: 2022-04
• Subjects: In-silico drug design -- SARS-CoV-2 -- Spike glycoprotein -- Peptide vaccine -- Computational model; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Medicine; Periodicals; 610
• DOI: 10.1016/j.mehy.2022.110810
• Languages: English
• ISSNs: 0306-9877

Abstract

Graphical abstract: Abstract: The far-reaching effects of the SARS-CoV-2 pandemic have crippled the progress of the world today. With the introduction of newer and newer mutated variants of the virus, it has become necessary to have a vaccine that remains useful against all the mutated strains of SARS-CoV-2. In this regard, peptide vaccines turn out to be a cheap alternative to the traditionally designed vaccines owing to their much quicker and computationally easier, and more robust design procedures. Here, in this article, we hypothesize that there are three possible peptide vaccine regions that can be targeted to prevent the surge of SARS-CoV-2. The candidates that were selected, were surface-exposed and were not sequestered by any neighbouring amino acids. They were also found to be capable of generating both B-cell and T-cell immune responses. Most importantly, none of them contains any spike protein mutation of the currently prevailing variants of SARS-CoV-2. From these findings, we have therefore concluded that these three regions can be used in wet labs for peptide vaccine design against the upcoming strains of SARS-CoV-2.